Abstract
Patients with Mycobacterium avium complex lung disease treated with amikacin liposome inhalation suspension (ALIS) at 2 clinics in the United States were surveyed to assess the frequency and management of ALIS-associated respiratory adverse events. Most respondents experienced these events, but management through physician-guided measures (eg, bronchodilator use, oral rinses, and/or temporary dosing adjustments) resulted in symptomatic improvement.
Highlights
Inhaled antibiotics serve an important role in the treatment of lung infections, in patients with chronic lung diseases that share similar infection pathways and disease processes [1,2,3,4]
We report patient perspectives obtained via a patientdirected survey regarding the techniques and strategies used in our clinics to manage respiratory adverse events associated with amikacin liposome inhalation suspension (ALIS)
ALIS is the only medication for refractory Mycobacterium avium complex (MAC) lung disease that is FDA approved
Summary
Inhaled antibiotics serve an important role in the treatment of lung infections, in patients with chronic lung diseases that share similar infection pathways and disease processes (eg, structural airway diseases including cystic fibrosis, bronchiectasis, chronic obstructive pulmonary disease, primary ciliary dyskinesia, and interstitial lung disease) [1,2,3,4]. Inhaled antibiotics may cause side effects, such as cough, dysphonia, bronchospasm, throat irritation, dyspnea, wheezing, and oropharyngeal pain. Respiratory adverse events included both upper airway (dysphonia, cough, oropharyngeal pain) and lower respiratory tract events (dyspnea, wheezing, bronchospasm) and tended to have an onset within the first month of treatment. Failure to adequately manage respiratory adverse events associated with inhaled antibiotics, including ALIS, may lead to poor treatment adherence and early discontinuation of an important therapeutic modality. We report patient perspectives obtained via a patientdirected survey regarding the techniques and strategies used in our clinics to manage respiratory adverse events associated with ALIS. This report is intended to provide insight into the management of these respiratory adverse events as practiced by patients and providers
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
